Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities

Radiation Increases Bioavailability of Lisinopril, a Mitigator of Radiation-Induced Toxicities

There are no FDA-approved drugs to mitigate the delayed effects of radiation exposure that may occur after a radiological attack or nuclear accident. To date, angiotensin-converting enzyme inhibitors are one of the most successful candidates for mitigation of hematopoietic, lung, kidney, and brain i...

Full description

Bibliographic Details
Main Authors: Meetha Medhora, Preeya Phadnis, Jayashree Narayanan, Tracy Gasperetti, Jacek Zielonka, John E. Moulder, Brian L. Fish, Aniko Szabo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
pharmacokinetics
renin-angiotensin system
delayed effects of radiation
pulmonary vasculature
mitigation
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.646076/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.646076/full

Similar Items